About the book
Clinically identified in 1997, mild cognitive impairment (MCI) represents a stage of age related cognitive decline often described as midway between deficits incurred in normal aging and those associated with dementia. Diagnosis of MCI is notably correlated with a greatly increased risk in incidence of dementia, ranging from 5 to 10 fold higher than the 1 % incidence level in the general population; hence, it is significant as a prognosticator and research domain. Its relationship to the progression of dementia, however, is complex, with high rates of reversion as well as variability in symptomatic expression, time course, and outcome. In Petersen's algorithm, for example, amnestic MCI is tasked to Alzheimer's dementia, whereas non-amnestic MCI devolves to frontotemporal lobular dementia. MCI's clinically complex diagnosis is increasingly well resolved with unique phenomenal subgroups now distinguished in terms of the impairments associated with amnestic and non- amnestic cognitive features. Relating these to underlying neural correlates, which may evolve to more severely impaired states of AD or other forms of dementia, and those that do not so evolve, however, remains an open but increasingly tractable problem that holds promise for therapy aimed at mitigating cognitive decline. This book will incorporate insights from diagnostic and dementia studies, as well as findings from a growing range of potential therapies that include transcranial magnetic stimulation, neuroplasticity and cognitive exercise, and dietary and pharmaco supplements. For a rapidly growing population at risk, the book promises up to date insights into positive prognostication and therapeutic possibility of this unique state of cognitive impairment.